GoodRx Holdings, Inc. - Class A Common Stock (GDRX)

GoodRx (GDRX) Q1 2026 Earnings Call Transcript

Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a ne...

What Happened? Shares of healthcare tech company GoodRx (NASDAQ:GDRX) jumped 7% in the afternoon session after the company reported first-quarter 2026 financ...

Healthcare tech company GoodRx (NASDAQ:GDRX) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, but sales fell by 4.4% year on year to $194 m...

GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx,” or the “Company”), the leading platform for medication savings in the U.S., has released its financial results for the first quarter of 2026.

Healthcare tech company GoodRx (NASDAQ:GDRX) will be announcing earnings results this Wednesday afternoon. Here’s what to look for. GoodRx beat analysts’ rev...

What Happened? Shares of healthcare tech company GoodRx (NASDAQ:GDRX) jumped 9.5% in the afternoon session after it announced it would provide access to Novo...

GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today announced that it is providing access to self-pay pricing for Novo Nordisk’s Ozempic® pill (oral semaglutide), helping eligible patients with type 2 diabetes obtain the medication for as low as $149 per month at pharmacies nationwide.

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how healthcare techno...

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...

GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading platform for prescription savings in the U.S., today announced it will release its first quarter 2026 financial results after U.S. markets close on Wednesday, May 6, 2026. GoodRx management will also hold a conference call and webcast the following morning, Thursday, May 7, 2026 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company’s business outlook.

GoodRx’s stock price has taken a beating over the past six months, shedding 40.7% of its value and falling to $2.31 per share. This was partly due to its sof...

What Happened? Shares of healthcare tech company GoodRx (NASDAQ:GDRX) jumped 3.6% in the afternoon session after the company announced it now offers access t...

GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today announced that the new higher dose Wegovy® HD (semaglutide) injection 7.2 mg is now available to eligible self-pay patients on GoodRx at $399 per month. Pricing scales with quantity, with a two-month supply available for $798 and a three-month supply available for $1,197, giving consumers flexibility and clear expectations around cost. For patients, Wegovy HD offers an additional FDA-approved step-up option within the Wegovy portfolio, potentially helping eligible patients achieve greater weight-loss benefit without requiring them to switch to a different brand or care pathway.

GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today announced that it is working with Eli Lilly and Company to expand access to the newly FDA-approved oral GLP-1 medication, Foundayo™ (orforglipron). Eligible self-pay patients can access Foundayo through GoodRx at a starting price of $149 per month, in line with the lowest available discounted cash price at launch. The offering provides transparent pricing and nationwide pharmacy access for the highly anticipated weight management treatment.

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not on...

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ...

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ...

GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today announced a new collaboration with Viatris, a global healthcare company, to make 17 of its established brand medications more affordable for consumers. Beginning today, eligible commercially insured patients may pay as low as $0–$4 on select Viatris medications through GoodRx. Cash-paying consumers, regardless of insurance status, can use GoodRx to access discounted cash prices of up to 85% off at more than 70,000 pharmacies nationwide. The collaboration includes widely prescribed, household-name medications such as Lipitor®, Celebrex®, Viagra®, and Norvasc®.

A number of stocks fell in the afternoon session after the February jobs report revealed an unexpected contraction in employment, with the healthcare industry showing significant job losses.

GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today announced employer-sponsored access to Zepbound® (tirzepatide) KwikPen® (for single-patient-use) through GoodRx Employer Direct. As one of Lilly’s Employer Connect independent program administrators, GoodRx enables self-insured employers to access Zepbound KwikPen at a set price of $449 across all doses, with the flexibility to further subsidize the cost for employees at the pharmacy counter.

A number of stocks fell in the afternoon session after a surprisingly hot wholesale inflation report fueled investor concerns about persistent price pressures. The Producer Price Index (PPI), a key measure of inflation at the wholesale level, increased by 0.5% in January, significantly higher than the 0.3% anticipated by economists. More concerning was the core PPI, which excludes volatile food and energy prices, as it surged by 0.8%, far exceeding the expected 0.3% rise. This data suggests that inflation may be more entrenched than previously thought, potentially impacting future interest rate decisions. In response to the news, major market indices, including the S&P 500, Dow Jones, and Nasdaq, all traded sharply lower as investors reassessed the economic outlook.

GoodRx (GDRX) Q4 2025 Earnings Call Transcript

Healthcare tech company GoodRx (NASDAQ:GDRX) reported Q4 CY2025 results exceeding the market’s revenue expectations, but sales fell by 1.9% year on year to $194.8 million. On the other hand, the company’s full-year revenue guidance of $765 million at the midpoint came in 6.2% below analysts’ estimates. Its non-GAAP profit of $0.09 per share was in line with analysts’ consensus estimates.